Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMGN779 in Relapsed/Refractory CD33-positive AML
NCT02674763Phase 1Completed
- Sponsor
- ImmunoGen
- Start
- Mar 2016
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of IMGN779 in acute myeloid leukemia (AML) (4 arms), sponsored by ImmunoGen. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Mar 2016; status: completed.
02
Drugs
IMGN779
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02674763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02674763.